Comparative study between two animal models of extrapyramidal movement disorders: Prevention and reversion by pecan nut shell aqueous extract

Behavioural Brain Research

Volumn 221, Issue 1, 2011, Pages 13-18

  Trevizol, Fabiola ^a   Benvegnú, Dalila M ^a   Barcelos, Raquel C S ^a   Pase, Camila S ^a   Segat, Hecson J ^a   Dias, Verônica Tironi ^a   Dolci, Geisa S ^a   Boufleur, Nardeli ^a   Reckziegel, Patrícia ^a   Burger, Marilise E ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Extrapyramidal disorders; Movement disorder; Orofacial dyskinesia; Pecan shells

Indexed keywords

ANTIOXIDANT; CARYA ILLINOENSIS EXTRACT; HALOPERIDOL; PLANT EXTRACT; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; CATALEPSY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; EXTRAPYRAMIDAL SYNDROME; MALE; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PECAN; PLANT MORPHOLOGY; PRIORITY JOURNAL; RAT;

ANIMALS; BASAL GANGLIA DISEASES; CARYA; CATALEPSY; DISEASE MODELS, ANIMAL; HALOPERIDOL; MALE; MOVEMENT DISORDERS; NUTS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, WISTAR; RESERPINE;

EID: 79952706006     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.02.026     Document Type: Article

References (46)

1. Egan M.F., Apud J., Wyatt R.J. Treatment of tardive dyskinesia. Schizophr Bull 1997, 23:583-609.
2. Awouters F., Niemegeers J.E., Janssen P.A.J. Tardive dyskinesia: etiological and therapeutic aspects. Pharmacopsychiatry 1990, 23:33-37.
3. Baldessarini R.J., Cole J.O., Davis J.M., Simpson G., Tarsy D., Gardos G., et al. Tardive dyskinesia: summary of attack force Report of the American Psychiatric Association. Am J Psychiatry 1980, 137:1163-1172.
4. Casey D.E. Tardive dyskinesia-pathophysiology. Pyschopharmacology: the fourth generation of progress 1995, 1497-1502. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
5. Kane J.M. Tardive dyskinesia epidemiological and clinical presentation. Psychopharmacology: the fourth generation of progress 1995, 1485-1495. Raven Press, New York. E.E. Bloom, D.J. Kupfer (Eds.).
6. Kulkarni S.K., Naidu P.S. Tardive dyskinesia: an update. Drugs Today 2001, 37:97-119.
7. Sachdev P., Saharov T., Cathcart S. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol Psychiatry 1999, 46:1672-1681.
8. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000, 61:5-9.
9. Abílio V.C., Vera J.A., Ferreira L.S., Duarte C.R., Carvalho R.C., Grassl C., et al. Effects of melatonin on orofacial movements in rats. Psychopharmacology 2002, 161:340-347.
10. Abílio V.C., Silva R.H., Carvalho R.C., Grassl C., Calzavara M.B., Registro S., et al. Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. Neuropharmacology 2004, 47:263-272.
11. Bilska A., Dubiel M., Sokołowska-Jezewicz M., Lorenc-Koci E., Włodek L. Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain. Neuroscience 2007, 146:1758-1771.
12. Bürger M.E., Alves A., Callegari L., Athayde F.R., Nogueira C.W., Rocha J.B. Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:135-140.
13. Busanello A., Barbosa N.B., Peroza L.R., Farias L.E., Burger M.E., Barreto K.P., et al. Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. Behav Pharmacol 2011, 22:71-75.
14. Dutra R.C., Andreazza A.P., Andreatini R., Tufik S., Vital M.A. Behavioral effects of MK-801 on reserpine-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:487-495.
15. Naidu P.S., Singh A., Kulkarni S.K. Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetina. Pharmacology 2004, 70:59-67.
16. Sussman A.N., Tran-Nguyen L.T.L., Neisewander J.L. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. Eur J Pharmacol 1997, 337:157-160.
17. Silva R.H., Abilio V.C., Torres-Leite D., Bergamo M., Chinen C.C., Claro F.T., et al. Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice. Behav Brain Res 2002, 132:171-177.
18. Teixeira A.M., Trevizol F., Colpo G., Garcia S.C., Charão M., Pereira R.P., et al. Influence of subchronic exercise on reserpine-induced oxidative stress in rats: behavioral and antioxidant evaluations. Pharmacol Biochem Behav 2008, 88:465-472.
19. Teixeira A.M., Reckziegel P., Müller L., Pereira R.P., Roos D.H., Rocha J.B.T., et al. Intense exercise potentiates oxidative stress in striatum of reserpine-treated animals. Pharmacol Biochem Behav 2009, 92:231-235.
20. Fuentes P., Paris I., Nassif M., Caviedes P., Segura-Aguilar J. Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell line-an experimental cell model for dopamine toxicity studies. Chem Res Toxicol 2007, 20:776-783.
21. Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia. Prog Neurobiol 2000, 61:525-541.
22. Barcelos R.C., Benvegnú D.M., Boufleur N., Reckziegel P., Müller L.G., Pase C., et al. Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter. Neurotox Res 2010, 17:228-237.
23. Bürger M.E., Fachinetto R., Wagner C., Perottoni J., Pereira R.P., Zeni G., et al. Effects of diphenyl-diselenide on orofacial dyskinesia model in rats. Brain Res Bull 2006, 70:165-170.
24. Colpo G., Trevizol F., Teixeira A.M., Pereira R.P., Rocha J.T.B., Burger M.E. Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats. Neurotox Res 2007, 12:171-180.
25. Teixeira A.M., Müller L.G., Reckziegel P., Boufleur N., Pase C.S., Villarinho J.G., et al. Beneficial effects of an innovative exercise model on motor and oxidative disorders induced by haloperidol in rats. Neuropharmacology 2011, 60:432-438.
26. Bürger M.E., Fachinetto R., Alves A., Callegari L., Rocha J.B.T. Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats. Brain Res 2005, 1031:202-210.
27. Bürger M.E., Fachinetto R., Zeni G., Rocha J.B.T. Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol Biochem Behav 2005, 81:608-615.
28. Fachinetto R., Bürger M.E., Wagner C., Wondracek D.C., Brito V.B., Nogueira C.W., et al. High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats. Pharmacol Biochem Behav 2005, 81:585-592.
29. Fachinetto R., Villarinho J.G., Wagner C., Pereira R.P., Ávila D.S., Bürger M.E., et al. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1478-1486.
30. Hashimoto T., Ross D.E., Gao X.M., Medoff D.R., Tamminga C.A. Mixture in the distribution of haloperidol induced oral dyskinesias in the rats supports an animal model of tardive dyskinesia. Psychopharmacology 1998, 137:107-112.
31. Konitsiotis S., Tsironis C., Kiortsis D.N., Evangelou A. Effects of N-methyl-d-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesia. Psychopharmacology 2006, 185:369-377.
32. Marchese G., Casu M.A., Bartholini F., Ruiu S., Saba P., Gessa G.L., et al. Sub-subchronic treatment with classic but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing. Eur J Neurosci 2002, 15:1187-1196.
33. Naidu P.S., Kulkarni S.K. Excitatory mechanisms in neuroleptic induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav Pharmacol 2001, 12:209-216.
34. Naidu P.S., Singh A., Kulkarni S.K. Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action. J Med Food 2003, 6:107-114.
35. Polydoro M., Schröder N., Lima M.N.M., Caldana F., Laranja D.C., Bromberg E., et al. Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 2004, 78:751-756.
36. Rogoza R.M., Fairfax D.F., Henry P., N-Marandi S., Khan R.F., Gupta S.K., et al. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia. Synapse 2004, 54:156-163.
37. Singh A., Naidu P.S., Kulkarni S.K. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-Induced orofacial dyskinesia. Eur J Pharmacol 2003, 477:87-94.
38. Prado A.C.P., Aragão A.M., Fett R., Block J.M. Phenolic compounds and antioxidant activity of Pecan [Carya illinoinensis (Wangenh.) C, Koch] kernel cake extracts. Gras Y Aceites 2009, 60:458-467.
39. Balmé F. Plantas medicinais 1982, Hemus Ltda, São Paulo.
40. Benvegnú D.M., Barcelos R.C.S., Boufleur N., Recziegel P., Pase C.S., Muller L.G., et al. Protective effects of a by-product of the pecan nut industry (Carya illinoensis) on the toxicity. J Environ Pathol Toxicol Oncol 2010, 29:185-197.
41. Villarreal-Lozoya J.E., Lombardini L., Cisneros-Zevallos L. Phytochemical constituents and antioxidant capacity of different pecan [Carya illinoinensis (Wangenh.) K. Koch] cultivars. Food Chem 2007, 102:1241-1249.
42. Rocha J.B., Santos J.E., Rocha L.K., Kleinpaul E.R. Undernutrition during suckling changes the sensitivity to haloperidol and chlorpromazine in two behavioural measures in weaning rats. Pharmacol Toxicol 1997, 81:114-123.
43. Langeveld C.H., Schepens E., Stoof J.C., Bast A., Drukarch B. Differential sensitivity to hydrogen peroxide of dopaminergic and noradrenergic neurotransmission in rat brain slices. Free Radic Biol Med 1995, 19:209-217.
44. Barcelos RCS, Benvegnú DM, Boufleur N, Pase C, Teixeira AM, Reckziegel P, et al. Short term dietary fish oil supplementation improves motor deficiencies related to reserpine-induced parkinsonism in rats. Lipids. doi:10.1007/s11745-010-3514-0.
45. Woods S.W., Morgenstern H., Saksa J.R., Walsh B.C., Sullivan M.C., Money R., et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010, 71:463-474.
46. Thaakur S., Himabindhu G. Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats. J Neural Transm 2009, 116:807-814.